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In this paper we describe a randomised controlled phase II trial of ribociclib in highrisk, localised, hormone sensitive prostate cancer. This novel trial aims to characterise the pharmacodynamics effects of an oral CDK4/6 inhibitor in prostate cancer.
Prostate cancer is the most common cause of cancer in men. Despite recent advances in its treatment, it remains the second leading cause of cancer death, and novel agents are required. CDK4/6 inhibitors have proven efficacy in breast cancer, and appear promising in preclinical models in prostate cancer.
The time between diagnosis and surgery for localised prostate cancer offers an ideal opportunity to examine pharmacodynamics effects of novel agents. This allows for a rational approach to decisions regarding which agents should be taken into phase II/III trials. This is the first study to investigate the pharmacodynamic effects of a CDK4/6 inhibitor in high-risk localised prostate cancer. It will also provide a model for similar trials with alternate novel agents.
We believe this protocol manuscript of a novel trial design investigating a novel agent, is ideally suited for BMJ open. This material is original research, has not been published previously and has not been submitted for publication elsewhere while under consideration. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of androgen receptor (AR) signalling or prostate biology other than inhibition of androgen synthesis or AR binding. Neoadjuvant pharmacodynamic studies allow for a rational approach to the decisions regarding which targeted therapies should progress to phase II/III trials. CDK4/6 inhibitors have evidence of efficacy in breast cancer, and have been shown to have activity in pre-clinical models of hormone sensitive and castrate resistant prostate cancer. The LEEP trial aims to assess the pharmacodynamic effects of LEE011 (ribociclib), an orally bioavailable and highly selective CDK4/6 inhibitor, in men undergoing radical prostatectomy for high-risk, localised prostate cancer.
Methods and analysis
The multicentre randomised, controlled 4:1 two arm, phase II, open label pharmacodynamic study will recruit 47 men with high risk, localised prostate cancer who are planned to undergo radical prostatectomy. Participants who are randomised to receive the study treatment will be treated with LEE011 400mg daily for 21 days for 1 cycle. The primary endpoint is the frequency of a 50% reduction in Ki-67 proliferation index from the pre-treatment prostate biopsy compared to that present in prostate cancer tissue from radical prostatectomy. Secondary and tertiary endpoints include pharmacodynamic assessment of CDK4/6 cell cycle progression via E2F levels, apoptotic cell death by cleaved caspase-3, changes in serum and tumour levels of PSA, pathological regression, safety via incidence of adverse events and exploratory biomarker analysis.
Ethics and dissemination
The protocol was approved by a central ethics review committee for all participating sites. Results will be disseminated in peer-reviewed journals and at scientific conferences.
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ARTICLE SUMMARY

Strengths and limitations of this study
 This is the first trial evaluating the pharmacodynamic effects of CDK4/6 inhibitors in hormone sensitive prostate cancer.  This study will explore potential biomarkers for treatment response  This trial is designed to examine anti-tumour pharmacodynamics effects of single agent ribociclib  This trial is not designed to determine whether a short course of neoadjuvant treatment could alter oncological outcomes or recurrence rates. These will be the next steps if the trial is positive. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Despite advances in the detection and treatment of prostate cancer, it remains the most common cause of cancer in men in the developed world and the second leading cause of cancer death 1 . Over the last decade, the treatment of advanced prostate cancer has changed dramatically with new therapies including novel anti-androgens 2 3 , novel taxanes 4 , radioisotope therapy 5 and more recently PARP inhibitors 6 . However these agents are not curative, and it is recognised that in order to improve survival from prostate cancer, it is critical to develop novel agents, particularly those that target aspects of androgen receptor (AR) signalling or prostate biology other than inhibition of androgen synthesis or AR binding 7 .
CDK4/6 inhibitors for treatment of prostate cancer
One of the common driving pathways that is altered in prostate cancer, and selected for in CRPC, is aberrant cell cycle activation through the cyclin/CDK/retinoblastoma (Rb) axis, with resultant uncontrolled cellular proliferation. This axis is critically important in controlling the G1-S transition of the cell cycle. There is evidence that androgens can stimulate the increased expression of G1 cyclins and cyclin-dependent kinases and decrease the expression of CDK inhibitors. The AR may also directly contribute to the transcription of some cell cycle regulatory genes, including cyclin D3 8 .
By binding to CDK4 and CDK6, selective CDK inhibitors inhibit Rb phosphorylation to prevent G1-S phase transition and induce cell cycle arrest. CDK4/6 inhibitors palbociclib (PD0332991; Pfizer), ribociclib (LEE011; Novartis) and abemaciclib (LY2835219; Eli Lilly) are oral and reversible small molecule inhibitors with high selectivity for CDK4 and CDK6, with evidence of efficacy in breast cancer [9] [10] [11] .
In preclinical models of hormone-sensitive and castration-resistant prostate cancer, palbociclib has exhibited single agent activity, by limiting cellular proliferation and growth 12 . The potential therapeutic effect was determined in both in vivo mouse xenografts and a novel ex vivo assay using primary human tumours obtained from radical prostatectomy. This ex vivo model has also shown that LEE011 significantly inhibits prostate tumour cell proliferation in a dose dependent manner (unpublished, Butler LM, 2019). This preclinical data provides evidence that CDK4/6 inhibitors achieve clinically relevant biological responses in human prostate tumours, and supports the evaluation of CDK4/6 inhibitors for treatment of prostate cancer.
Towards more rapid assessment of new therapies
Clinical trials of new drugs in the hormone sensitive phase of prostate cancer (high-risk localised prostate cancer, or at relapse after localised treatment) require long follow-up due to the natural history of the disease. The interval between biopsy and surgery offers an ideal opportunity for in vivo assessment of anti-tumour activity and selection of optimal novel agents for further investigation. A recent systematic review identified that a lack of a biomarker-driven strategy and failure to achieve "proof of concept" in Phase 2 trials were significantly associated with failure of cancer drugs to achieve late-stage clinical success such as FDA approval 13 . Neoadjuvant pharmacodynamic studies, such as the one described in this project, will allow for a more rational approach to the decisions regarding which targeted therapies should go forward into phase II/III trials.
Biomarkers for treatment response
The identification of informative biomarkers in the pre-clinical phase, which can be incorporated into clinical studies, is pivotal to accelerating the drug development process, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y and when incorporated into clinical decision-making, can maximise patient benefit and minimise harm, with judicious drug administration. Candidate biomarkers will be identified/assessed in this clinical trial and potentially validated in future trials with CDK4/6 inhibitors.
Absent or decreased staining of nuclear Rb proteins is commonly found in prostate cancer specimens, and it has been suggested that inactivation of the retinoblastoma gene may be an important event in prostate tumour progression 14 . In an ex vivo model, functional Rb is required for optimal CDK4/6 inhibitor efficacy 12 . There is evidence that cyclin D1 overexpression is implicated in tumourigenesis and tumour progression, and may be related to the evolution to castration resistance in prostate cancer 15 . The product of the INK4A gene inactivates the G1-phase cyclin dependent kinases CDK4 and CDK6. Overexpression of p16INK4A in high-grade prostatic epithelial neoplasia is associated with early relapse in prostate cancer patients treated with radical prostatectomy 16 . Given the role of Cyclin D1, Rb proteins and p16INK4A in cell cycle progression, there is interest in reviewing these as biomarkers of response to CDK4/6 inhibitors. Further, induction of cyclin D1 and p16INK4A have been identified as possible pharmacodynamic endpoints on pre-clinical models, and can be validated in a clinical setting 12 17 .
HYPOTHESIS
Primary hypothesis
We hypothesise that administration of LEE011 (Ribociclib) to men prior to undergoing radical prostatectomy will lead to a 50% reduction in Ki-67 index in 30% or more of participants treated with LEE011, compared with a 50% reduction in Ki-67 index in 10% or fewer in the control group.
Secondary hypothesis
We hypothesise that treatment with LEE011 will be associated with inhibition of CDK4/6 cell cycle progression by a decrease in the level of E2F in prostate cancer tissue, and an increased level of cleaved caspase-3 in prostate tissue indicating increased apoptotic activity.
METHODS AND ANALYSIS
The LEEP study is an Australian-based, multicentre, randomised controlled, phase II, open label pharmacodynamic study. The primary aim is to determine the pharmacodynamic activity of the CDK4/6 inhibitor LEE011 in men with high-risk localised prostate cancer undergoing radical prostatectomy.
Study objectives
The primary objective of this study is to determine the effect of LEE011 on tumour cell proliferation, as determined by:
 The frequency of a 50% reduction in the Ki-67 proliferation index from the pretreatment prostate biopsy compared to that present in prostate cancer tissue from radical prostatectomy.
The secondary objectives are to determine:
 The effect of LEE011 on CDK4/6 cell cycle progression, by measuring E2F expression in prostate tissue by immunohistochemistry and peripheral blood mononuclear cells by ELISA 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The tertiary objectives are to evaluate exploratory biomarkers as predictors of response to therapy. These include Rb status, cyclin D1 amplification, p16INK4a expression, PTEN loss, AR amplifications/mutations and aberrations of PI3K signalling pathways (assessed by reverse transcription-PCR and FISH analysis of cancer tissue from radical prostatectomy). These will also be tested in free plasma DNA, through a novel technique that has identified these aberrations in circulating tumour DNA 18 . Effects on immune system such as circulating T-cell profiling will also be assessed.
Trial oversight and monitoring
The LEEP study is a collaboration between the Chris O'Brien Lifehouse, Sydney; Royal Prince Alfred Hospital, Sydney; the University of Adelaide, Adelaide; St Vincent's Hospital, Sydney; and the National Health and Medical Research Council (NHMRC) Clinical Trials Centre (CTC), University of Sydney.
The University of Sydney is the study sponsor. The NHMRC CTC will be responsible for study co-ordination, monitoring, data acquisition, management and statistical analysis.
Safety and efficacy endpoints will be assessed when evaluable tissue is available from 22 participants treated with LEE011 and at study completion.
Protocol amendments can only be made by the trial management committee, and must be approved by the central institutional Human Research Ethics Committee (HREC) prior to implementation.
Patient and public involvement
This research was funded through a granting process that included a consumer representative from Cancer Voices NSW. The grant, study protocol and patient information sheet/consent form were all discussed, reviewed and edited by our consumer representative. A consumer representative is a member of the trial steering committee. Following completion, a plain-English version of the results will be made available to patients via their study doctor. Results of this study will be disseminated to study participants through peer-reviewed journals, at scientific conferences, and on the NHMRC CTC website.
Trial design
The protocol consists of a randomised, Patients who fulfil all of the following characteristics will be considered eligible for enrolments:
Inclusion Criteria
 Males ≥ 18 years with localised prostate cancer and at least clinical stage T3a Or Gleason score of between 8 and 10 Or Preoperative PSA ≥ 20 ng/mL AND planned for radical prostatectomy;  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;  Histological confirmation of prostate cancer via a pre-treatment diagnostic transrectal ultrasound (TRUS) biopsy;  Adequate bone marrow, hepatic and renal function;  Serum calcium, potassium, phosphate and magnesium within normal range or corrected with supplements.
Exclusion criteria
Patients with the following characteristics will be excluded from study enrolment:
 Major surgery ≤ 2 weeks prior to enrolment or who have not recovered from side effects of such therapy. TRUS biopsy is not considered major surgery in this study;  Known hypersensitivity to the study drug or its excipients;  Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g.
Gilbert's syndrome);  Diarrhoea ≥ CTCAE grade 2;  Impaired cardiac function, including any one of the following: This study will use LEE011, an orally bioavailable, highly selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cellcycle progression and inducing G1 phase arrest. Based on the results of preclinical toxicology studies and available clinical safety data, the main adverse reactions for LEE011 are bone marrow suppression including leukopenia, neutropenia, anaemia and thrombocytopaenia, dyspnoea, hepatic toxicity, renal toxicity, fatigue, nausea, vomiting, diarrhoea and prolongation of the QT interval. The risk of these toxicities may be amplified by concomitant administration of strong inhibitors of CYP3A4 or other combination treatments.
Randomisation
The method of randomisation with be minimisation with stratification by site. Participants will be allocated to the study treatment in a ratio of 4:1 (LEE011:control).
Recruitment and consent
Patient screening and enrolment will be overseen by the site principal investigator and performed by trained study personnel. Patients will provide written informed consent prior to study enrolment. Treatment will be planned to start within 7 days after randomisation.
Study procedures
The randomised, controlled, phase II, open label, pharmacodynamic study will assess the pharmacodynamic activity of the CDK4/6 inhibitor LEE011, in men with high-risk, localised prostate cancer.
Participants randomised to receive the study treatment will have a pre-treatment MUGA. Participants will receive LEE011 400mg daily taken orally for 21 days treatment for 1 cycle. The scheduled surgery will occur 22 days after the first dose of LEE011 (if randomised to study drug treatment) or 22 days after randomisation (if randomised to the control group). Dose modifications are not permitted in this study. Patients who need to come off the study due to toxicity will discontinue and proceed to surgery as planned.
Data acquisition
Tumour tissue samples will be collected at transrectal biopsy and at radical prostatectomy. Blood samples for biomarker analysis and PSA will be collected within 7 days prior to randomisation, weekly during treatment and at the time of radical prostatectomy.
Ki-67 expression will be assessed by pathologist review. Where possible, for all analyses, comparisons will be made between similar areas in the needle biopsy and radical prostatectomy specimens. Scoring for protein expression will be performed by two independent pathologist researchers, both blinded to the treatment groups and pairings of tissue from the same patient. Discrepancies will be resolved by consensus.
Cell cycle arrest will be measured by E2F expression as determined by immunohistochemistry and scored by manual counting. Apoptotic cell death will be determined by examining the cleaved caspase-3 staining in tumour cells by immunohistochemistry and scored by manual counting. PSA levels in tumour and blood will be assessed by immunoassay, with immunohistochemistry or ELISA.
Trial data will be monitored by clinical trials program staff from the NHMRC CTC. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Sample size estimation
Using the Simon's two-stage design, an uninteresting rate for the true response is 10% and a clinically interesting rate, which would warrant further investigation, is 30%. Based on this design, a sample size of 37 patients will have at least 90% power with 95% confidence to exclude the uninteresting rate in favour of the more clinically meaningful rate. A response is defined as ≥50% decrease in Ki-67 expression in the paired prostate biopsy baseline sample compared with the radical prostatectomy sample.
A futility analysis will be performed after 22 patients have completed 1 cycle of LEE011 and are evaluable for pharmacodynamic response. If there are 2 or fewer responses, consideration will be given to either reassessing the study design or stopping the study due to futility. When these 22 patients are assessed it is expected that there will be at least 6 patients in the control group, which will allow for assessment of the response to be performed in light of what is seen in the control arm. The study will then recruit an additional 15 patients in the treatment arm and 4 controls. This sample size allows for a modest number of drop-outs/loss to follow up. It is anticipated that at least 33 patients in the treated cohort will be evaluable for response at study completion.
10 untreated men will be enrolled in the control group to provide estimates of PD biomarkers as a basis for biological comparison, giving a total sample size of 47 patients.
It is expected that none of the control group men will have a ≥50% decrease in Ki-67. For the secondary objectives, the sample size of 10 control participants to 37 treated patients provides adequate power to detect large differences only.
Patients who do not receive study treatment, withdraw their consent or are not evaluable will be replaced.
Statistical analysis
Analysis of efficacy endpoints (i.e. response, biomarkers) will include only evaluable patients. Analysis of safety endpoints (i.e. toxicity) will be according to treatment received, including only patients who received at least 1 dose of the experimental treatment.
The response in each treatment arm will be summarised by the number and proportion of patients experiencing at least a 50% decrease in Ki-67 expression, with a two-tailed p-value significance level of 0.05. Ki-67 levels pre-and post-treatment will also be summarised for each treatment arm using standard descriptive statistics.
Analyses of secondary endpoints will include descriptive summaries. Continuous data will be compared using t-tests where appropriate and categorical data using chi-squared tests.
ETHICS AND DISSEMINATION
The study will be conducted according to the Note for Guidance on Good Clinical Practice 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 To this end, no patient will be recruited to the study until all the necessary approvals have been obtained and the patient has provided written informed consent. Further, the investigator shall comply with the protocol, except when a protocol deviation is required to eliminate immediate hazard to a subject. In this circumstance the NHMRC CTC, principal investigator and HREC must be advised immediately.
The protocol was approved by a central ethics review committee (St Vincent's Hospital HREC) for all participating sites (HREC/17/SVH/294).
TRIAL STATUS
Patient enrolment for the study commenced in November 2018 at the Chris O'Brien Lifehouse in NSW, Australia. To date, 5 patients have been enrolled, with anticipated enrolment to allow for the futility assessment by the first quarter in 2020. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Methods and analysis
Ethics and dissemination
The protocol was approved by a central ethics review committee (St Vincent's Hospital HREC) for all participating sites (HREC/17/SVH/294). Results will be disseminated in peer-reviewed journals and at scientific conferences.
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ARTICLE SUMMARY
Strengths and limitations of this study
 This is the first trial evaluating the pharmacodynamic effects of CDK4/6 inhibitors in hormone sensitive prostate cancer.  This study will explore potential biomarkers for treatment response  This trial is designed to examine anti-tumour pharmacodynamics effects of single agent ribociclib  This trial is not designed to determine whether a short course of neoadjuvant treatment could alter oncological outcomes or recurrence rates. These will be the next steps if the trial is positive. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
INTRODUCTION
Despite advances in the detection and treatment of prostate cancer, it remains the most common cause of cancer in men in the developed world and the second leading cause of cancer death 1 . Over the last decade, the treatment of advanced prostate cancer has changed dramatically with new therapies including novel anti-androgens 2 3 , novel taxanes 4 , radioisotope therapy 5 and more recently PARP inhibitors 6 . However these agents are not curative, and it is recognised that in order to improve survival from prostate cancer, it is critical to develop novel agents, particularly those that target aspects of androgen receptor (AR) signalling or prostate biology other than inhibition of androgen synthesis or AR binding 7 .
CDK4/6 inhibitors for treatment of prostate cancer
Towards more rapid assessment of new therapies
Clinical trials of new drugs in the hormone sensitive phase of prostate cancer (high-risk localised prostate cancer, or at relapse after localised treatment) require long follow-up due to the natural history of the disease. The interval between biopsy and surgery offers an ideal opportunity for in vivo assessment of anti-tumour activity and selection of optimal novel agents for further investigation. Both Ki67 and Cleaved Caspase 3 have been used to assess pharmacodynamic activity of novel therapies in neoadjuvant studies in prostate and breast cancer [13] [14] [15] . Ki67 reduction has also been found to correlate with response in neoadjuvant studies in breast cancer 16 17 , and with outcome in prostate cancer 18 . However there can be significant intra-tumour Ki67 heterogeneity, particularly in high risk prostate cancer 19 , as well as inter-reader variability in its measurement 20 . Where possible, centralised review of Ki67 in clinical trials is advisable 18 .
A recent systematic review identified that a lack of a biomarker-driven strategy and failure to achieve "proof of concept" in Phase 2 trials were significantly associated with failure of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 cancer drugs to achieve late-stage clinical success such as FDA approval 21 . Neoadjuvant pharmacodynamic studies, such as the one described in this project, will allow for a more rational approach to the decisions regarding which targeted therapies should go forward into phase II/III trials.
Biomarkers for treatment response
The identification of informative biomarkers in the pre-clinical phase, which can be incorporated into clinical studies, is pivotal to accelerating the drug development process, and when incorporated into clinical decision-making, can maximise patient benefit and minimise harm, with judicious drug administration. Candidate biomarkers will be identified/assessed in this clinical trial and potentially validated in future trials with CDK4/6 inhibitors.
Absent or decreased staining of nuclear Rb proteins is commonly found in prostate cancer specimens, and it has been suggested that inactivation of the retinoblastoma gene may be an important event in prostate tumour progression 22 . In an ex vivo model, functional Rb is required for optimal CDK4/6 inhibitor efficacy 12 . There is evidence that cyclin D1 overexpression is implicated in tumourigenesis and tumour progression, and may be related to the evolution to castration resistance in prostate cancer 23 . The product of the INK4A gene inactivates the G1-phase cyclin dependent kinases CDK4 and CDK6. Overexpression of p16INK4A in high-grade prostatic epithelial neoplasia is associated with early relapse in prostate cancer patients treated with radical prostatectomy 24 . Given the role of Cyclin D1, Rb proteins and p16INK4A in cell cycle progression, there is interest in reviewing these as biomarkers of response to CDK4/6 inhibitors. Further, induction of cyclin D1 and p16INK4A have been identified as possible pharmacodynamic endpoints on pre-clinical models, and can be validated in a clinical setting 12 25 .
HYPOTHESIS
Primary hypothesis
Secondary hypothesis
METHODS AND ANALYSIS
Study objectives
The primary objective of this study is to determine the effect of LEE011 on tumour cell proliferation, as determined by: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The tertiary objectives are to evaluate exploratory biomarkers as predictors of response to therapy. These include Rb status, cyclin D1 amplification, p16INK4a expression, PTEN loss, AR amplifications/mutations and aberrations of PI3K signalling pathways (assessed by reverse transcription-PCR and FISH analysis of cancer tissue from radical prostatectomy). These will also be tested in free plasma DNA, through a novel technique that has identified these aberrations in circulating tumour DNA 26 . Effects on immune system such as circulating T-cell profiling will also be assessed.
Trial oversight and monitoring
The LEEP study is a collaboration between the Chris O'Brien Lifehouse, Sydney; Royal Prince The University of Sydney is the study sponsor. The NHMRC CTC will be responsible for study co-ordination, monitoring, data acquisition, management and statistical analysis. Safety and efficacy endpoints will be assessed when evaluable tissue is available from 22 participants treated with LEE011 and at study completion.
Patient and public involvement
This research was funded through a granting process that included a consumer representative from Cancer Voices NSW. The grant, study protocol and patient information sheet/consent form were all discussed, reviewed and edited by our consumer representative. A consumer representative is a member of the trial steering committee. Following completion, a plain-English version of the results will be made available to patients via their study doctor. Results of this study will be disseminated to study participants through peer-reviewed journals, at scientific conferences, and on the NHMRC CTC website. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Inclusion Criteria
Patients who fulfil all of the following characteristics will be considered eligible for enrolments:
 Males ≥ 18 years with high-risk localised prostate cancer (at least clinical stage T3a
Or Gleason score of between 8 and 10 Or Preoperative PSA ≥ 20 ng/mL) AND planned for radical prostatectomy;  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;  Histological confirmation of prostate cancer via a pre-treatment diagnostic transrectal ultrasound (TRUS) biopsy;  Adequate bone marrow, hepatic and renal function;  Serum calcium, potassium, phosphate and magnesium within normal range or corrected with supplements.
Exclusion criteria
Gilbert's syndrome);  Diarrhoea ≥ CTCAE grade 2;  Impaired cardiac function, including any one of the following: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  Prior treatment with a CDK4/6 inhibitor;  Patients who are currently receiving treatment with strong CYP3A4 inhibitors and cannot be discontinued or switched to an alternative treatment prior to commencing study treatment  Patients receiving chronic or high-dose corticosteroid therapy;  Significant infection, including chronic active hepatitis B, hepatitis C or HIV;  Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
Investigational medical product -LEE011 (ribociclib)
This study will use LEE011, an orally bioavailable, highly selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cellcycle progression and inducing G1 phase arrest. Based on the results of preclinical toxicology studies and available clinical safety data, the main adverse reactions for LEE011 are bone marrow suppression including leukopenia, neutropenia, anaemia and thrombocytopaenia, dyspnoea, hepatic toxicity, renal toxicity, fatigue, nausea, vomiting, diarrhoea and prolongation of the QT interval. The risk of these toxicities may be amplified by concomitant administration of strong inhibitors of CYP3A4 or other combination treatments.
Randomisation
The method of randomisation will be minimisation with stratification by site. Participants will be allocated to the study treatment in a ratio of 4:1 (LEE011:control).
Recruitment and consent
Study procedures
Participants randomised to receive the study treatment will have a pre-treatment MUGA. Participants will receive LEE011 400mg daily taken orally for 21 days treatment for 1 cycle. The scheduled surgery will occur 22 days after the first dose of LEE011 (if randomised to study drug treatment) or 22 days after randomisation (if randomised to the control group). Dose modifications are not permitted in this study. Patients who need to come off the study due to toxicity (e.g. neutropenia or thrombocytopaenia) will discontinue and proceed to surgery as planned.
Local pharmacy departments will record drug recept including a pill count to assess compliance.
Study samples will be stored at the Garvan Institute for Medical Research.
Data acquisition
Tumour tissue samples will be collected at transrectal biopsy and at radical prostatectomy. Blood samples for biomarker analysis and PSA will be collected within 7 days prior to randomisation, weekly during treatment and at the time of radical prostatectomy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Ki-67 expression will be assessed by central pathologist review. Where possible, for all analyses, comparisons will be made between similar areas in the needle biopsy and radical prostatectomy specimens. Scoring for protein expression will be performed by two independent pathologist researchers from Royal Prince Alfred Hospital, both blinded to the treatment groups and pairings of tissue from the same patient. Discrepancies will be resolved by consensus.
Trial data will be monitored by clinical trials program staff from the NHMRC CTC.
STATISTICAL CONSIDERATIONS
Sample size estimation
Statistical analysis
The response in each treatment arm will be summarised by the number and proportion of patients experiencing at least a 50% decrease in Ki-67 expression, with a two-tailed p-value significance level of 0.05. Ki-67 levels pre-and post-treatment will also be summarised for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Analyses of secondary endpoints will include descriptive summaries. Continuous data will be compared using t-tests where appropriate and categorical data using chi-squared tests.
ETHICS AND DISSEMINATION
The study will be conducted according to the Note for Guidance on Good Clinical Practice To this end, no patient will be recruited to the study until all the necessary approvals have been obtained and the patient has provided written informed consent. Further, the investigator shall comply with the protocol, except when a protocol deviation is required to eliminate immediate hazard to a subject. In this circumstance the NHMRC CTC, principal investigator and HREC must be advised immediately.
Results will be disseminated in peer-reviewed journals and at scientific conferences. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
DATA AVAILABILITY
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Instructions to authors
In your methods section, say that you used the SPIRITreporting guidelines, and cite them as: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Statistics: additional analyses #20b Methods for any additional analyses (eg, subgroup and adjusted analyses)
8-9
Statistics: analysis population and missing data #20c Definition of analysis population relating to protocol nonadherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) 8
Methods: Monitoring
Data monitoring: formal committee #21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed 5 Data monitoring: interim analysis #21b Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Auditing #23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor 5
Ethics and dissemination
Research ethics approval #24 Plans for seeking research ethics committee / institutional review board (REC / IRB) approval 9, 10
Protocol amendments #25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators) 9
Consent or assent #26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) 7 Consent or assent: ancillary studies #26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable NA Confidentiality #27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial 8, 9
Declaration of interests #28 Financial and other competing interests for principal investigators for the overall trial and each study site 10 Data access #29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators 10 Ancillary and post trial care #30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation NA Dissemination policy: trial results #31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions 5 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
